Compromised longevity due to Mycobacterium abscessus pulmonary disease in lungs scarred by tuberculosis

References

1. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175:367–416 [View Article]
   [Google Scholar]
2. Daley CL, Griffith DE. Pulmonary disease caused by rapidly growing mycobacteria. Clin Chest Med 2002; 23:623–632
   [Google Scholar]
3. Greendyke R, Byrd TF. Differential antibiotic susceptibility of Mycobacterium abscessus variants in biofilms and macrophages compared to that of planktonic bacteria. Antimicrob Agents Chemother 2008; 52:2019–2026 [View Article]
   [Google Scholar]
4. Maurer FP, Bruderer VL, Ritter C, Castelberg C, Bloemberg GV et al. Lack of antimicrobial bactericidal activity in Mycobacterium abscessus . Antimicrob Agents Chemother 2014; 58:3828–3836 [View Article]
   [Google Scholar]
5. Standards NCfCL Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes; Approved Standard. Wayne, PA: NCCLS; 2003
6. Cremades R, Santos A, Rodríguez JC, Garcia-Pachón E, Ruiz M et al. Mycobacterium abscessus from respiratory isolates: activities of drug combinations. J Infect Chemother 2009; 15:46–48 [View Article]
   [Google Scholar]
7. Oh CT, Moon C, Park OK, Kwon SH, Jang J. Novel drug combination for Mycobacterium abscessus disease therapy identified in a Drosophila infection model. J Antimicrob Chemother 2014; 69:1599–1607 [View Article]
   [Google Scholar]
8. Zhang Z, Lu J, Song Y, Pang Y. In vitro activity between linezolid and other antimicrobial agents against Mycobacterium abscessus complex. Diagn Microbiol Infect Dis 2018; 90:31–34 [View Article]
   [Google Scholar]
9. Kaushik A, Makkar N, Pandey P, Parrish N, Singh U et al. Carbapenems and rifampin exhibit synergy against Mycobacterium tuberculosis and Mycobacterium abscessus . Antimicrob Agents Chemother 2015; 59:6561–6567 [View Article]
   [Google Scholar]
10. Nessar R, Cambau E, Reyrat JM, Murray A, Gicquel B. Mycobacterium abscessus: a new antibiotic nightmare. J Antimicrob Chemother 2012; 67:810–818 [View Article]
    [Google Scholar]
11. Novosad SA, Beekmann SE, Polgreen PM, Mackey K, Winthrop KL et al. Treatment of Mycobacterium abscessus infection. Emerg Infect Dis 2016; 22:511–514 [View Article]
    [Google Scholar]
12. Floto RA, Olivier KN, Saiman L, Daley CL, Herrmann JL et al. US cystic fibrosis foundation and European cystic fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis. Thorax 2016; 71:1–22 [View Article]
    [Google Scholar]
13. Jarand J, Levin A, Zhang L, Huitt G, Mitchell JD et al. Clinical and microbiologic outcomes in patients receiving treatment for Mycobacterium abscessus pulmonary disease. Clin Infect Dis 2011; 52:565–571 [View Article]
    [Google Scholar]
14. Nash KA, Brown-Elliott BA, Wallace RJ Jr. A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae . Antimicrob Agents Chemother 2009; 53:1367–1376 [View Article]
    [Google Scholar]
15. Kaushik A, Gupta C, Fisher S, Story-Roller E, Galanis C et al. Combinations of avibactam and carbapenems exhibit enhanced potencies against drug-resistant Mycobacterium abscessus . Future Microbiol 2017; 12:473–480 [View Article]
    [Google Scholar]
16. Story-Roller E, Maggioncalda EC, Cohen KA, Lamichhane G. Mycobacterium abscessus and β-lactams: emerging insights and potential opportunities. Front Microbiol 2018; 9:2273 [View Article]
    [Google Scholar]
17. Tanaka E, Kimoto T, Tsuyuguchi K, Suzuki K, Amitani R. Successful treatment with faropenem and clarithromycin of pulmonary Mycobacterium abscessus infection. J Infect Chemother 2002; 8:252–255 [View Article]
    [Google Scholar]
18. Woodcock JM, Andrews JM, Brenwald NP, Ashby JP, Wise R. The in-vitro activity of faropenem, a novel oral penem. J Antimicrob Chemother 1997; 39:35–43
    [Google Scholar]
19. Diel R, Ringshausen F, Richter E, Welker L, Schmitz J et al. Microbiological and clinical outcomes of treating non-Mycobacterium avium complex nontuberculous mycobacterial pulmonary disease: a systematic review and meta-analysis. Chest 2017; 152:120–142 [View Article]
    [Google Scholar]